Comparative efficacy of halcinonide and fluocinonide creams in psoriasis and eszematous dermatoses. 1975

A Sudilovsky, and T H Clewe

The clinical efficacy of halcinonide and fluocinonide creams was compared in the treatment of 392 patients with corticosteroid-responsive dermatoses, including psoriasis, and various eczematous dermatoses such as atopic dermatitis, eczematous dermatitis, and neurodermatitis. The severity of the condition treated was moderate or severe in most of the patients. Usually, the creams were applied three times daily for two to three weeks. In psoriasis, halcinonide was superior to fluocinonide (P less than 0.05). There was no significant difference between halcinonide and fluocinonide in the treatment of the eczematous dermatoses. Both creams were well tolerated, each being associated with local side effects (such as burning sensation, dryness, erythema, and pruritus) in 4.9 per cent of patients.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011282 Pregnenediones Unsaturated pregnane derivatives containing two keto groups on side chains or ring structures. Diketopregnenes,Dioxopregnenes
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004485 Eczema A dermatitis characterized by a spongiotic tissue reaction pattern occurring as a reaction to many endogenous and exogenous agents. Dermatitis, Eczematous,Eczematous Dermatitis
D005260 Female Females

Related Publications

A Sudilovsky, and T H Clewe
September 1985, International journal of dermatology,
A Sudilovsky, and T H Clewe
September 1976, International journal of dermatology,
A Sudilovsky, and T H Clewe
October 1972, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society,
A Sudilovsky, and T H Clewe
December 1974, Minnesota medicine,
A Sudilovsky, and T H Clewe
April 1974, The British journal of dermatology,
A Sudilovsky, and T H Clewe
January 1979, International journal of dermatology,
A Sudilovsky, and T H Clewe
July 1969, Die Quintessenz,
A Sudilovsky, and T H Clewe
October 1986, International journal of dermatology,
Copied contents to your clipboard!